Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Crohn's Disease Endoscopic REmission Definition in an Objective Way (CREDO1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03498625
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : April 11, 2019
Sponsor:
Collaborators:
AbbVie
Biogen
Celgene
Gilead Sciences
Roche Pharma AG
Takeda
Information provided by (Responsible Party):
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Brief Summary:

The CDEIS (Crohn's disease endoscopic index of severity) and its derivative, SES-CD (single endoscopic score for Crohn's disease) were constructed to evaluate the endoscopic severity of Crohn's disease (CD). The current therapeutic goal in CD is endoscopic remission, which is thought to be predictive of a favourable evolution of the disease. However, up to now there is no measure of endoscopic remission, objectively constructed and validated, not even a consensus for its definition. An objective measure of endoscopic remission is necessary, notably for the evaluation of new treatments, a request of the regulatory agencies (FDA and EMA), but also in clinical practice if one wishes to adapt the treatment of patient according to the level of endoscopic remission.

The aim of the study is to construct a measure of endoscopic remission based on an objective assessment (depth or grade) of remission, that must be reproducible, little or not dependent on the reader interpreting the endoscopy.

The CREDO 1 program is a cross-sectional study designed to construct objectively a measure of the endoscopic remission of CD through an index measuring its depth or a score measuring its grade and to evaluate its reproducibility.

This study is composed of four main parts:

  1. Training and selection of readers:

    • Selection and definition of all lesions to be studied at consensus meetings, first between the central readers, then with the participation of local investigators.
    • Specific training of local investigators in the recognition of endoscopic lesions
    • Checking the performance of the central readers
  2. Recruitment of patients by investigators - local readers:

    • Inclusion criteria: CD diagnosed for more than 6 months, in clinical remission for at least 3 months, with a Crohn's disease activity index < 150 at the time of endoscopy.
    • Each local investigator will have to record 15 videos divided according to his/her overall judgment into 3 status of remission: Complete Remission; Remission almost complete; Remission neither complete nor nearly complete.
    • The colon will be divided into 7 segments: ileum, ileocecal valve, right colon, transverse colon, descending colon, sigmoid colon and rectum. Each segment will be identified by landmarks.
    • Videos will be anonymized and then centralized at a healthcare provider (OVH - SAS).
    • 16 French and Belgian centers will participate in the study leading to a total of 240 films.
  3. Analysis of videos by central readers:

    • 12 central readers will independently read 80 out of the 240 videos
    • Videos allocation to central readers will be performed through balanced incomplete block method to ensure that each central reader, as well as each central reader pair, has the same weight in achieving the results.
    • A quantitative evaluation of the depth of endoscopic remission on a visual analogue scale and a qualitative evaluation of the grade of remission on a 5-level ordinal scale will be provided by each central reader, segment by segment and globally, in addition to the description of all lesions identified by segment.
  4. Analysis of the data recorded by the central readers:

    • An index (depth of remission) or score (grade of remission) will be constructed from linear or multiple logistic regression models, considering the reader and endoscopy as random factors, to take into account the dependence between the readings performed on different endoscopies by the same central reader or on the same endoscopy by different readers.
    • Variations in readings between central readers will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.

In an observational longitudinal multi-center cohort study (CREDO 2), it will be tested whether the index or score thus constructed is able to predict prolonged clinical remission for 2 years in patients in clinical remission at baseline. If this test is successful, we will have a primary objective and reproducible criterion for evaluating treatments in CD and a useful tool for the management of these patients in clinical practice.


Condition or disease Intervention/treatment Phase
CD Diagnostic Test: Colonoscopy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Crohn's Disease Endoscopic REmission Definition in an Objective Way
Actual Study Start Date : March 13, 2018
Estimated Primary Completion Date : March 13, 2020
Estimated Study Completion Date : March 13, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Clinical remission CD Diagnostic Test: Colonoscopy
Colonoscopy for CD patients in clinical remission




Primary Outcome Measures :
  1. Building an objective definition of the depth or grade of endoscopic remission in relation to what is observed during endoscopy in CD patients presenting with clinical remission [ Time Frame: 1 Year ]
    12 Central Readers, selected from the participating centers independent of the patient selection will be involved in the central reading process. They will have experience in IBD endoscopy and its evaluation and will be involved in the lesions' selection that need to be described during videos' readings. Videos allocation will be done by a randomized balanced incomplete block design. Each CR will review 80 videos and each video will be read by 4 CR (6 couples of 2 CR). The efficacy of this design is 0.90, meaning that this design has the same power than a complete design with a sample size reduced by 10% whereas the reading burden is reduced by 67% (80 instead of 240). Six videos, two of each remission status randomly selected, will be read a second time by the CRs to assess intra observer variability. The CR will provide the detection and quantification of the lesions in the endoscopic images, and a quantitative and qualitative remission evaluation


Secondary Outcome Measures :
  1. Intra- and inter-observer variability of what is observed during endoscopy in CD [ Time Frame: 1 Year ]
    For each observed segment, the central reader will first evaluate the quality of the bowel preparation and the recording, secondly the CR documents all lesions, detected or not, and quantified those detected, then the CR will perform his/her segmental endoscopic remission evaluation, qualitative on a 5-grade scale and quantitative on a linear analogue scale. Finally, after the readings of all segments, the CR will provide his/her global endoscopic remission evaluations, qualitative on a 5-grade scale and quantitative on a linear analogue scale. Each CR will review 80 videos and each video will be read by 4 CR (6 couples of 2 CR). Based on the this the inter-observer variability will be assessed. Six videos, two of each remission status randomly selected, will be read a second time in a random order by each of the 12 CRs to assess intra observer variability.

  2. Intra- and inter-observer variability of depth and grade of endoscopic remission in CD [ Time Frame: 1 Year ]

    For the quantitative evaluation, the CR had to:

    • provide his/her evaluation of depth of remission per segment (ileum, ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum) in marking a cross on a linear analog scale, with left extremity being absolutely no remission and right extremity being absolutely complete remission. The evaluation needs to be done directly after the viewing of the segment not at the end of the viewing of the complete recording.
    • provide his/her evaluation of the depth of remission globally in marking a cross on a linear analog scale, with left extremity being absolutely no remission and right extremity being absolutely complete remission. The global evaluation needs to be done after the viewing of the complete recording. This global evaluation is not necessarily equal to the maximum or to the mean of the segmental evaluations.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥18 years of age
  2. Established CD for more than 6 months with histopathological confirmation available in the medical records of the patient
  3. Clinical remission as considered by the investigators global assessment ≥3 consecutive months
  4. Clinical remission defined as CDAI <150 at the moment of the endoscopy and CRP <5 mg/l and fecal calprotectin <250 µg/g
  5. Planned ileocolonoscopy for CD
  6. All treatments for CD are allowed
  7. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

  1. Pregnancy at time of endoscopy
  2. People unable to give their consent (because of their physical or mental state).
  3. Absence of written consent.
  4. Ulcerative colitis or IBD type unclassified
  5. Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy
  6. Less than 3 evaluable ileocolonic segments (Incomplete recording of the endoscopy or more than three resected ileocolonic segments (not counting ileocecal valve)) in CREDO 2
  7. Non-steroidal anti-inflammatory drugs intake within two weeks before baseline endoscopy
  8. Perianal fistulizing CD without luminal disease
  9. Contraindication for endoscopy
  10. Inaccessible ileocolonic segment even after attempt of endoscopic balloon dilation
  11. Suspicion of gastrointestinal infection within 4 weeks prior to baseline endoscopy
  12. Documented active or suspicion of intestinal tuberculosis
  13. Conditions which in the opinion of the investigator may interfere with the subject's ability to comply to the follow up with the study procedures.
  14. Exclusive CD of the upper gastrointestinal tract (Montreal classification L4)
  15. Montreal classification L1 without terminal ileal involvement
  16. Colon preparation with solutions other than macrogol or picosulphate solutions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03498625


Contacts
Layout table for location contacts
Contact: Yoram Bouhnik, MD. PhD 00 33 6 20 47 22 52 yoram.bouhnik@gmail.com

Locations
Layout table for location information
Belgium
Leuven University Hospital Not yet recruiting
Leuven, Belgium, 3000
Contact: Peter Bossuyt, MD    +32 4 98 72 56 47    peter.bossuyt@Imelda.be   
Principal Investigator: Peter Bossuyt, MD         
France
APHP- Hopital BEAUJON Recruiting
Clichy, France, 92110
Contact: YORAM BOUHNIK, MD       yoram.bouhnik@gmail.com   
Principal Investigator: YORAM BOUHNIK, MD         
Sponsors and Collaborators
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
AbbVie
Biogen
Celgene
Gilead Sciences
Roche Pharma AG
Takeda
Investigators
Layout table for investigator information
Principal Investigator: Yoram Bouhnik, MD PhD Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Principal Investigator: Peter Bossuyt, MD Universitaire Ziekenhuizen Leuven

Layout table for additonal information
Responsible Party: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
ClinicalTrials.gov Identifier: NCT03498625    
Other Study ID Numbers: GETAID 2017-001
2017-003345-15 ( EudraCT Number )
First Posted: April 17, 2018    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: ND

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases